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Introduction
Multiple sclerosis (MS) is a chronic neurodegen-
erative disorder characterized by inflammation 
and progressive neurological destruction and 
degeneration.1 The disease is associated with a 
wide range of symptoms including motor, sen-
sory, and cognitive impairments, which lead to 
gradual worsening of disability.1,2 Although 
chronic and incurable, MS has only a limited 
effect on life expectancy,3 so patients with MS 
require long-term treatment and this places a 
significant burden on healthcare resources in 
terms of time and cost. Both specialized care from 
an attending physician and suitable healthcare 
infrastructure are needed to support effective 
long-term treatment. Also, monitoring of each 
patient’s treatment response, based on clinical 
events and magnetic resonance imaging (MRI) 
findings, is needed to ensure that patients with 
breakthrough disease are identified early, so that 
therapy can be changed to reduce the risk of fur-
ther disease progression.4,5
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Abstract
Background: As patients with multiple sclerosis (MS) require lifelong treatment, optimization 
of therapy with respect to efficacy and safety is needed to limit long-term disease progression. 
Patients with MS also need a range of health-related services. Satisfaction with these as 
well as treatment is clinically relevant because satisfied patients are more likely to adhere 
to therapy. The aim of this study was to determine the status of patient satisfaction and of 
healthcare services in 70 specialized MS centres in Germany.
Methods: In 2011, patients with MS responded to a questionnaire, which solicited clinical and 
demographic information, as well as patients’ perceptions of their overall situation and their 
satisfaction with treatment.
Results: Of 2791 patients surveyed, 81.9% had relapsing-remitting MS with mild disability 
[mean (standard deviation) Expanded Disability Status Scale score: 2.6 (1.8)]. Disease activity 
data were collected from 2205 patients, of whom 57.6% had remained relapse-free during 
the preceding 12 months. However, 38.9% had experienced one or more relapses, most of 
whom (67.3%) while receiving immunomodulatory treatment. About one-third of the patients 
indicated that they were more dissatisfied with their overall situation compared with the 
time before diagnosis. However, many patients (58.3%) were satisfied with their existing 
medication. Overall, 72.8% of patients would prefer oral to injectable treatments, assuming 
there was no difference in their efficacy.
Conclusions: A substantial proportion of patients experienced breakthrough disease on 
treatment and may potentially benefit from a change of therapy. Although largely satisfied 
with treatment, most patients with MS would choose oral over injectable treatments.
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It is clinically relevant to evaluate the extent to 
which patients with MS are satisfied with treat-
ment, with healthcare services, and with the dis-
ease-related information they receive6 because 
satisfied patients are more likely both to comply 
with therapy7 and to participate actively in man-
aging their disease.8 Promoting a high level of 
patient satisfaction is therefore desirable to ensure 
the best clinical outcomes. Also, healthcare pro-
fessionals’ perceptions of patient status, including 
physical disability and health-related quality of 
life, may differ from those perceived by the 
patient.9,10 Thus, it is important to understand 
patients’ perspectives when trying to improve the 
quality of treatment and of healthcare services.11
The impact of dissatisfaction with treatment on 
adherence is of particular concern among patients 
with MS.12 For instance, it has been demon-
strated that when patients adhere to therapy in 
the long-term, relapse rates can be reduced and 
functional and cognitive abilities and quality of 
life can be enhanced.6,13,14 However, two factors 
may constrain adherence to MS therapy. First, 
extended periods when significant symptoms do 
not occur may cause patients to question the need 
for long-term treatment.15 It is, therefore, impor-
tant to provide patients with reliable information 
that allows them to understand their prognosis, 
subclinical disease progression and the benefit of 
persisting with treatment.16 Secondly, many dis-
ease-modifying drugs require frequent parenteral 
administration, predominantly by self-injection. 
Anxiety about self-injection, and injection-site 
disorders may lead to treatment interruption or 
discontinuation.6,17,18
Patients with MS not only require specialized 
treatment, but also reliable long-term care meas-
ures and health-related services. Beyond assess-
ment of treatment satisfaction, analysis of patient 
satisfaction needs to consider factors such as a 
patient’s overall satisfaction with their physical, 
mental, social and occupational status; their per-
ceived needs concerning health-related services; 
and their expectations for further treatment. To 
meet the various needs of patients with MS, spe-
cialized centres have been established in Germany 
that offer a comprehensive approach to MS 
healthcare. In addition to treatment, these cen-
tres offer educational programmes to improve 
patient understanding of the condition, and of 
the need for adherence to, and the potential ben-
efits of treatment. Specialist MS nurses also 
attend these centres to provide information on 
support services and to advise patients on the 
management of disease symptoms and of adverse 
effects associated with treatment.
The survey reported here was conducted in 2011, 
when fewer disease-modifying therapies were 
licensed and the first oral disease-modifying ther-
apy in MS [fingolimod (Gilenya®), Novartis 
Pharma AG, Basel, Switzerland] had only just 
been approved. The aim of the survey was to eval-
uate the status of patient satisfaction and the 
healthcare situation in 70 specialized MS centres 
in Germany. Data were obtained by question-
naires that recorded clinical data as well as treat-
ment satisfaction and patients’ perceptions of 
their overall situation. The rate and reasons for 
treatment discontinuation were also examined, 
and patients were asked through questionnaires 
about their perception of unmet needs in the 
ongoing development of MS drugs.
Methods
Participants and procedures
This anonymous, cross-sectional survey was con-
ducted in 70 specialized MS centres in Germany 
between March and June 2011. Patients were eli-
gible if they were diagnosed with ‘clinically defi-
nite’ MS,19 and if informed consent was given 
(n = 2791). Data were collected using question-
naires designed specifically for the survey, and 
that had been tested in a pilot study conducted 
between October 2010 and February 2011. 
Questionnaires were completed either during 
routine clinic visits or during specially arranged 
appointments.
Questionnaire
Demographic data and clinical characteristics 
were collected retrospectively. Demographic data 
comprised age, sex, occupational status, and mar-
ital status. Clinical characteristics included onset 
of disease, duration of disease and treatment, and 
MS subtypes [clinically isolated syndrome (CIS), 
relapsing-remitting MS (RRMS), secondary pro-
gressive MS (SPMS), primary progressive MS 
(PPMS)]. Disability was scored using Kurtzke’s 
Expanded Disability Status Scale (EDSS).20 In 
addition, information was collected about 
patients’ most recent MRI investigations (num-
ber of lesions in T2-weighted MRI) and about the 
number and severity of relapses in the preceding 
12 months.
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Questions on perceived needs and satisfaction 
were answered by patients in the presence of a 
health professional. This patient-directed part of 
the questionnaire included: one question on 
whether treatment was eventually discontinued 
or interrupted; five multiple choice questions to 
rate the advantages and disadvantages of their 
current medication, their reasons for treatment 
discontinuation, their preferred way of obtaining 
information, and the frequency with which infor-
mation was obtained; and six items listing several 
statements about which patients were asked to 
indicate their level of agreement using a pivoted 
5-point Likert scale (1, strongly agree; 2, agree; 3, 
neither agree nor disagree; 4, disagree; 5, strongly 
disagree). These statements focused on patients’ 
satisfaction with their current situation and medi-
cation as well as their perceived needs for improve-
ments in therapy.
Statistics
Questionnaire data were reported descriptively 
and expressed as mean ± standard deviation 
(SD) or as the percentage of participants. The 
top-two-box score refers to the percentage of 
patients who awarded an agreement score of 1 or 
2 when asked to give their level of agreement with 
a statement using the Likert scale. Patients were 
also stratified based on their preferred drug 
administration route. Comparisons between 
groups of patients were performed by a Student’s 
t test. The Chi-square test was used to assess sta-
tistical differences among categorical variables. A 
p-value ⩽0.05 was considered significant. The 
statistical analyses were performed with GESS 
tabs 4.0 (Gesellschaft für Software in der 
Sozialforschung mbH, Hamburg, Germany).
Results
A total of 2791 patients participated in the sur-
vey; demographic and clinical characteristics are 
summarized in Table 1. In 71% of patients, MS 
was diagnosed within 2 years of the onset of symp-
toms and the duration of diagnostic delay tended 
to increase with disease duration (Figure 1). 
Overall treatment duration was 2 years or less in 
27.1% of patients, 3–5 years in 26.4%, and 6 
years or more in 42.8%. The duration of current 
therapy was 2 years or less in 44.2% of patients, 
3–5 years in 27.4% and 6 years or more in 22.7%. 
Most patients had T2 lesions (no lesions, 4.6%; 
1–8 lesions, 33.9%; >8 lesions, 61.5%) with an 
average T2 lesion load of 11.8 (Table 2) at the 
most recent MRI scan (performed <1 year ago in 
Table 1. Demographic and clinical characteristics of participants.
Total CIS RRMS SPMS/PPMS
Patients with MS (N) 2791 49 2285 370
Women (%) 72.5 87.8 72.7 69.5
Age, years (mean ± SD) 41.4 ± 11.0 33.4 ± 10.3 40.0 ± 10.5 50.5 ± 9.2
Married/ living with a partner (%) 73.0 63.3 73.7 70.3
Employed (%) 55.2 57.1 60.7 23.5
Time from symptom onset to 
diagnosis, years (mean ± SD)
1.7 ± 3.8 0.7 ± 3.4 1.6 ± 3.5 2.9 ± 5.2
MS subtypes
 RRMS (%) 81.9 – 100 –
 SPMS (%) 11.7 – – 88.1
 CIS (%) 1.8 100 – –
 PPMS (%) 1.6 – – 11.9
Disability status
 EDSS-score (mean ± SD) 2.6 ± 1.8 1.0 ± 0.8 2.2 ± 1.5 5.0 ± 1.8
 EDSS-score 0.0–2.0 (%) 50.2 91.8 57.1 7.8
 EDSS-score 2.5–4.0 (%) 25.9 4.1 26.9 23.7
 EDSS-score 4.5–5.0 (%) 5.7 0 4.2 15.9
 EDSS-score ⩾ 5.5 (%) 10.0 0 5.0 43.5
CIS, clinically isolated syndrome; EDSS, expanded disability status scale; MS, multiple sclerosis; PPMS, primary 
progressive MS; RRMS, relapsing–remitting MS; SD, standard deviation; SPMS, secondary progressive MS.
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61.4% of patients). Overall, 38.9% of patients 
had a relapse in the preceding year (Table 2). For 
65.9% (n = 380) of the patients who relapsed 
while on therapy, information on T2 lesion count 
was available. Almost all had T2 lesions (<9 
lesions: 28.4%; ⩾9 lesions: 70.6%).
About one-third of the patients reported negative 
impact of the disease on their lives (Table 3). In 
total, 58.3% of the patients reported to be satis-
fied or very satisfied with their therapy (Table 4). 
However, 43.2% of patients reported having dis-
continued or interrupted therapy at least once. 
Treatment discontinuation occurred more fre-
quently in patients with longer disease duration 
and in patients who reported being rather dissat-
isfied with the efficacy of their MS medication 
than in other groups (Figure 2). Reasons reported 
for discontinuation were general side effects 
(57.5%), injection-site reactions (38.7%), insuf-
ficient efficacy (32.6%), and complex administra-
tion (19.1%). Ideal requirements of MS treatment 
from the patients’ perspective are summarized in 
Table 5. Based on an assumption that all new 
medications are equally effective, the majority of 
patients indicated that their first-choice route of 
administration would be oral (72.8%), with few 
ranking subcutaneous, intravenous or intramus-
cular administration as preferred routes (Figure 
3). For oral administration, patients indicated 
that tablets and capsules were preferred to liquid 
drug forms (54.5% versus 18.3%, respectively). 
Baseline demographic and disease characteristics 
were similar in the group of patients who ranked 
oral administration as a very important improve-
ment (n = 651) and in the group that ranked 
it as unimportant or very unimportant (n = 332). 
Comfortable use was ranked far more important 
among patients who considered oral administra-
tion important (Table 6) and injection-site reac-
tions and complexity of administration were more 
frequently perceived as disadvantage in this group 
(Table 7). Other subgroup analyses (geographic 
variables, MS subtypes) revealed no differences 
in patient satisfaction. The preferred source of 
information for MS patients is a physician/neu-
rologist (Table 8).
Discussion
In this large survey of approximately 2800 
patients treated in specialized MS centres in 
Germany, more than half of patients had not 
experienced a relapse in the preceding year. 
However, more than one-third had relapsed dur-
ing that time, many while receiving immunomod-
ulatory treatment. The survey also identified that 
>20% of patients had MRI disease activity, that 
is Gd-enhancing lesions at their last scan. This 
situation might be improved by better monitor-
ing to detect breakthrough disease, more timely 
treatment review, and a more individualized 
approach to treatment than was practised when 
this survey was conducted in 2011.21 Changes in 
the intervening period to Deutsche Gesellschaft 
für Neurologie MS treatment guidelines, which 
now differentiate between mild, moderate and 
(highly) active forms of MS, suggest that practice 
is moving in this direction.22 The fact that treat-
ment optimization has become more achievable 
accentuates the need to detect and address a 
suboptimal treatment response early and so min-
imize disease progression and long-term neuro-
logical damage.23
Figure 1. Duration of diagnostic delay versus disease duration (N = 2736).
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Over the last 5 years, assessment of MS worsening 
and progression has increasingly employed com-
bination measures of clinical and MRI disease 
activity, with a shift towards using such measures 
to evaluate therapeutic effectiveness.24–27 Although 
these combination measures continue to evolve, 
their proliferation tends to support the notion that 
the MS community is increasingly accepting of 
the concept of treating to such optimized treat-
ment goals.28 For therapy to be most effective it 
Table 2. Disease progression data (T2-weighted MRI lesion number, and relapse number and severity).
Total CIS RRMS SPMS/ 
PPMS
Patients with MS (n) 2205 33 1838 274
MRI
 Most recent MRI (date ± SD years) 2009.4 ± 2.1 2008.3 ± 8.8 2009.6 ± 1.7 2008.7 ± 2.5
 Number of T2 lesions (mean ± SD) 11.8 ± 10.0 7.7 ± 5.6 11.6 ± 9.5 13.9 ± 13.4
  Patients with Gd-enhancing lesions at last 
scan (%)
22.4 33.3 22.9 18.2
MS relapse
  Relapse in the last 12 months (%)  
(n = 857)
38.9 60.6 40.4 27.8
  Relapse under immunomodulatory 
therapy (%) (n = 557)
30.4 3.0 32.5 20.8
  Number of relapses within previous year 
(mean ± SD)
0.6 ± 1.1 0.8 ± 0.7 0.6 ± 1.1 0.4 ± 0.9
  Complete or almost complete remission (%) 60.0 72.7 65.8 20.1
 Partial or minor remission (%) 23.2 18.2 19.8 47.1
  Ongoing relapse or no remission (%) 4.2 6.0 3.3 9.8
Signs of disability progression
 Yes (%) 20.1 6.1 14.4 59.9
 No (%) 72.7 84.8 79.2 29.9
CIS, clinically isolated syndrome; MRI, magnetic resonance imaging; MS, multiple sclerosis; PPMS, primary progressive 
MS; RRMS, relapsing–remitting MS; SD, standard deviation; SPMS, secondary progressive MS.
Table 3. Patients’ perception of their overall situation and functional impairments, patients who scored top-
two boxes (%)a (N = 2791).
Statement Total CIS RRMS SPMS/PPMS
My daily life is affected by MS 35.3 18.4 29.9 71.9
My professional life is affected by MS 35.7 20.4 31.9 61.9
My physical activity is affected by MS 40.9 20.4 35.4 78.9
I suffer from premature fatigue 47.1 26.5 44.4 65.7
I have difficulties in concentrating 33.9 24.5 31.5 47.8
I suffer from mood swings and depression 29.3 20.4 27.7 39.2
I am more dissatisfied than before MS diagnosis
With my overall situation 27.2 18.4 23.8 48.9
With my physical situation 35.9 18.4 31.2 65.7
With my mental situation 28.1 16.3 26.3 40.5
With my occupational situation 28.4 12.2 25.9 46.5
With my social situation 19.6 8.2 17.7 32.7
aData are based on a five-point Likert scale, where 1 = ‘strongly agree’, 2 = ‘agree’, 3 = ‘neither agree nor disagree’, 4 = 
‘disagree’, and 5 = ‘strongly disagree’.
bTop-two box score refers to the percentage of patients (N = 2791) who scored a 1 or a 2.
CIS, clinically isolated syndrome; MS, multiple sclerosis; PPMS, primary progressive MS; RRMS, relapsing–remitting MS; 
SD, standard deviation; SPMS, secondary progressive MS.
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must also begin as early as possible, so it was 
encouraging that this study found an apparent 
reduction over time in the delay between symp-
tom onset and diagnosis.
The survey identified a relatively high degree of 
patient satisfaction with the efficacy and tolera-
bility of their existing medication. However, 
rates of treatment discontinuation were substan-
tial (nearly half of patients had discontinued or 
interrupted therapy) and these rates increased 
with both disease duration and the level of dis-
satisfaction with therapy which is in line with 
Haase and colleagues.6 Discontinuation was 
mainly attributable to general side effects and 
injection-site reactions. Consistent with this, 
adverse effects such as flu-like symptoms29 and 
injection-site reactions30 have been reported as 
reasons for treatment discontinuation. In terms 
of adherence, most patients reported general 
side effects and, to a lesser degree, injection-site 
reactions and the complexity of administering 
Table 4. Patients’ satisfaction with efficacy and tolerability of the MS medication (N = 2791).
Rating score 1 2 3 4 5 No response
Total  
 Efficacy (%) 22.5 35.8 25.3 7.9 2.8 5.8
 Tolerability (%) 21.9 36.4 25.5 8.4 2.4 5.3
CIS  
 Efficacy (%) 36.7 28.6 20.4 4.1 2.0 8.2
 Tolerability (%) 22.4 38.8 18.4 8.2 – 12.2
RRMS  
 Efficacy (%) 23.6 38.2 24.4 6.5 1.8 5.6
 Tolerability (%) 22.5 37.5 25.1 7.8 2.3 4.8
SPMS/PPMS  
 Efficacy (%) 11.4 22.7 31.6 18.1 8.9 7.3
 Tolerability (%) 16.5 28.6 31.4 12.7 3.2 7.6
Values are expressed as the percentage of patients who reported each level of satisfaction with the efficacy and 
tolerability of their MS medication. Patients rated their scores on a five-point Likert scale, where 1 = ‘very satisfied’, 2 = 
‘satisfied’, 3 = ‘neither satisfied nor dissatisfied’, 4 = ‘slightly dissatisfied’, and 5 = ‘very dissatisfied.
CIS, clinically isolated syndrome; MS, multiple sclerosis; PPMS, primary progressive MS; RRMS, relapsing–remitting MS; 
SPMS, secondary progressive MS.
Table 5. Ideal requirements of a new MS treatment, patients who scored top-two boxes (%)a (N = 2791).
Total CIS RRMS SPMS/ 
PPMS
Reduction of relapses 91.7 91.8 94.0 78.9
Prevention of health status deterioration 93.1 91.8 93.3 93.5
Fewer side effects 85.8 79.6 86.6 82.7
Reduced inflammatory activity in MRI 85.2 89.8 86.7 76.2
Safe use 84.8 83.7 85.6 80.8
Comfortable use 78.9 71.4 80.0 73.0
Reduction of everyday problems 78.4 83.7 77.9 81.1
Possibility of long-term therapy (>8 years) 76.3 61.2 78.0 70.0
Oral administration 65.9 67.3 67.3 59.2
Regular intake 61.6 61.2 62.1 57.3
aData are based on a five-point Likert scale, where 1 = ‘very important’, 2 = ‘important’, 3 = ‘neither important or 
unimportant’, 4 = ‘unimportant’, and 5 = ‘very unimportant’.
bTop-two box score refers to the percentage of patients (N = 2791) who scored each criterion a 1 or a 2.
CIS, clinically isolated syndrome; MRI, magnetic resonance imaging; MS, multiple sclerosis; PPMS, primary progressive 
MS; RRMS, relapsing–remitting MS; SPMS, secondary progressive MS.
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therapy, as crucial factors. Disease-related fac-
tors, such as neuropsychological complications, 
can also impact adherence, and treatment of 
depression has been shown to increase adher-
ence to interferon β-1b therapy.31 Fatigue was 
rated as the most burdensome symptom in this 
survey and as it has been identified as one of the 
most common adverse events leading to treat-
ment discontinuation.15 Symptomatic treatment 
of fatigue should be targeted as a matter of clini-
cal routine in MS.32
As well satisfaction with treatment, this survey 
explored what requirements patients would 
like to see fulfilled in MS therapies to guide 
their further development. Most patients stated 
that reduced relapse rates, delayed disease pro-
gression, less MRI inflammatory activity, and 
therapies suitable for long-term use would all 
be desirable. Such answers demonstrate how 
well-informed these patients were, both about 
their medical condition and about MS patho-
genesis in general. As reported elsewhere,33  
the internet was identified in this study as an 
important source of information for patients. 
However, participants identified their neurolo-
gist as a primary information source, which 
also tends to suggest a good physician-patient 
relationship.34 Notably, a recent study in MS 
patients identified the physician-patient rela-
tionship as important in influencing long-term 
treatment adherence.35
Table 6. Requirements for future MS therapies stated by patients who preferred oral administration.
Oral administration Difference (p)
 Importanta  
(n = 651)
Unimportantb  
(n = 332)
Reduction of relapses 1.3 ± 0.7 1.2 ± 0.7 NS
Prevention of health status deterioration 1.2 ± 0.6 1.3 ± 0.7 NS
Fewer side effects 1.4 ± 0.9 1.8 ± 1.1 <0.01
Reduced inflammatory activity in MRI 1.4 ± 0.7 1.6 ± 1.0 <0.01
Safe use 1.4 ± 0.7 1.9 ± 1.2 <0.01
Comfortable use 1.5 ± 0.7 2.4 ± 1.3 <0.01
Reduction of everyday problems 1.9 ± 1.1 1.8 ± 1.1 NS
Possibility of long-term therapy (>8 years) 1.7 ± 1.0 2.1 ± 1.3 <0.01
Oral administration 1.0 ± 0.0 4.5 ± 0.5 <0.01
Regular intake 2.3 ± 1.3 2.7 ± 1.5 <0.01
Data are expressed as mean ± SD and are based on a five-point Likert scale, where 1 = ‘very important’, 2 = ‘important’, 
3 = ‘neither important or unimportant’, 4 = ‘unimportant’, and 5 = ‘very unimportant’.
aMean ± SD scores of patients who had ranked oral administration as very important.
bMean ± SD scores of patients who had ranked oral administration as unimportant or very unimportant.
MS, multiple sclerosis; MRI, magnetic resonance imaging; NS, not significant; SD, standard deviation.
Table 7. Perceived disadvantages of currently used medications stated by patients who preferred oral 
administration (% responses).
Oral administration Difference (p)
 Importanta (n = 651) Unimportantb (n = 332)
Side effects 51.9 50.0 NS
Injection-site reactions 51.0 41.0 <0.01
Complexity of administration 33.9 20.2 <0.01
Insufficient efficacy 20.1 22.9 NS
aPercentage of responses from patients who had ranked oral administration as very important.
bPercentage of responses from patients who had ranked oral administration as unimportant or very unimportant.
Multiple responses were possible.
NS, not significant.
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Studies of treatment adherence in MS have 
reported discontinuation rates ranging from 27% 
during the first 6 months of treatment 36 to 46% 
over a 4.2-year follow up.37 Notably, patients 
with RRMS who adhere to disease-modifying 
therapies have been shown to have a significantly 
better quality of life, fewer neuropsychological 
complications, and shorter duration of disease 
and treatment than nonadherent patients.13 It is 
difficult to quantify the relationship between 
adherence and MRI outcomes, but adherent 
patients probably experience greater benefit from 
treatment36 and may, therefore, be at lower risk 
for disease progression.
Among strategies being explored to improve 
adherence, oral drug administration has been very 
promising. This survey found that if new medica-
tions were equally effective, most patients would 
prefer oral to injectable therapy, and oral adminis-
tration has been shown to be associated with 
higher levels of patient satisfaction than injectable 
therapies.38,39 A total of three oral MS treatments 
Figure 2. Treatment discontinuation frequency versus (a) disease duration (N = 2736) and (b) satisfaction with 
medication efficacy (N = 2577).
Satisfaction was rated on a five-point pivoted Likert scale, in which 1 = ‘very satisfied’, 2 = ‘satisfied’, 3 = ‘neither satisfied 
nor dissatisfied’, 4 = ‘slightly dissatisfied’, and 5 = ‘very dissatisfied).
Table 8. Preferred source of information of patients 
with MS (N = 2791).
Source of information Survey 
participants (%)
Personal contacts
 Physician/neurologist 94.6
 MS nurse 52.8
 Family, partner, friends 30.4
 Telephone hotline 11.3
Internet
 Internet (in general) 64.3
  Homepage of the German 
multiple sclerosis society
35.4
 Manufacturer’s homepage 13.1
 Internet chatrooms 11.5
Print
 Manufacturer’s information 36.5
 Newspaper 35.0
 Books 30.5
 Other 15.2
MS, multiple sclerosis.
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are now approved: fingolimod (Gilenya®),40 terif-
lunomide (Aubagio®),41 and dimethyl fumarate 
(Tecfidera®).42 After a switch from injectable ther-
apy to fingolimod for example, patients reported 
an increase in treatment satisfaction.43 With 
respect to adherence, a recent analysis did not 
observe differences between oral medication and 
injectable disease-modifying therapies. However, 
this analysis was based on a 12-month period 
only, and only 10% of the patients included were 
on oral medication.44 Future studies will show to 
what extent oral drugs have a positive impact on 
long-term adherence in MS.
Negative expectations towards a therapy, for 
example the expectation of adverse drug effects, 
can trigger nocebo effects that affect adherence.45 
Patient management thus needs to address 
patients’ expectations towards a therapy in order 
to increase adherence. Patients with somatoform 
disorder comorbidities like depression or anxiety 
disorders are often less adherent to medication 
than patients without these comorbidities. As 
such disorders are frequent in MS patients, their 
contribution to adherence needs to be consid-
ered. Adequate treatment of these comorbidities 
may increase adherence.46
In terms of patients’ levels of satisfaction with their 
overall situation and with different aspects of their 
lives, about one-third of participants were dissatis-
fied with their situation, compared with the time 
before diagnosis. Patients had also experienced 
impairments to both their daily and professional 
lives, and suffered from more restricted physical 
activity. Several studies have shown that patients 
with MS are rather dissatisfied with healthcare-
related matters such as rehabilitation, coordination 
of services, availability of MS-related informa-
tion,47–49 and their current situation in general.50 
Consistent with this, about one-third of the partici-
pants in our study expressed dissatisfaction with 
different physical, psychological, and vocational 
aspects of their lives. Among patients with progres-
sive forms of MS the proportion was higher than in 
the total population. The effect of MS on neuro-
logical and neuropsychiatric functions,51 the unpre-
dictability of the disease course, and the relatively 
young age of patients at diagnosis all conspire to 
impact severely on patients’ personal development. 
It is perhaps unsurprising that patients with MS 
report lower levels of satisfaction with their lives 
than do healthy individuals52 or patients with other 
chronic diseases, such as inflammatory bowel dis-
ease, rheumatoid arthritis, and diabetes.53,54
Conclusion
Our survey aimed to assess satisfaction and the 
healthcare-related services of patients treated in 
specialized MS care centres in Germany and 
showed that patients were rather satisfied with 
the efficacy and tolerability of their existing med-
ication, and with healthcare professionals in gen-
eral. The survey did highlight some dissatisfaction 
among patients with aspects of their situation, 
Figure 3. Preferred route of administration (N = 2791).
The graph depicts the proportion of patients who rated each route of administration for a new MS medication as their first 
choice on a scale of 1–5, where 1 represented the patient’s first choice and 5 their last choice. Equal efficacy of the MS 
preparations was assumed.
MS, multiple sclerosis.
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and further studies could examine how this could 
be improved, based on how patient satisfaction 
in the cohort changes over time. The levels of 
disease breakthrough observed indicate that a 
substantial proportion of patients were also 
receiving suboptimal treatment, which should be 
possible to address given the increased number 
of treatment options available to patients with 
MS since the survey was conducted. Based on 
preferences expressed in this survey, treatment 
adherence may be more likely if patients with MS 
can choose oral instead of injectable therapies.
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